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1. Introduction
Forty years ago Mario Rizzeto’s group identified a new antigen-antibody system (delta
antibody and delta antigen (HDAg)) in HBsAg carriers with severe hepatitis [1, 2]. Further
experiments in chimpanzees showed that this HDAg marked transmissible pathogen requires
coexistence of HBV infection for its life cycle, proving its defective nature which requires
HBsAg for transmission and replication [3]. As the cause of hepatitis D was identified, a virion
particle (Figure 1.) composed of outer coat containing HBV envelope proteins (HBsAg) and
inner nuclocapsid was described [4]. Internal nuclear like structure is comprised of single
stranded, circular RNA molecule of 1700 nucleotides associated with two distinctive forms of
hepatitis D antigen (HDAg), small and large subunit [5, 6]. Although HDV in its structure
possesses HBsAg, HDV is classified as separate pathogen with own genus called Deltavirus [7].
This unusual virus is the smallest infectious pathogen in human virology, with unique
replication cycle unknown to animal cells. During replication process a viral RNA is transcri‐
bed by hosts RNA polymerases [8], which usually transcribe DNA molecules, and after
transcription HDV RNA is cleaved by its own ribozyme [9].
Dependence on the HBsAg presence results in two patterns of HDV infection. HDV can be
transmitted simultaneously with HBV (co-infection pattern) or infection may occur at preced‐
ing HBV infected individual (super-infection pattern). Due to differences of HDV acquisition
clinical course and outcome of HDV infection varies. However, many studies have shown that
HDV infection causes more severe liver disease [10] and more rapid progression to cirrhosis
[11] than HBV mono-infection alone.
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Although many details regarding HDV viral cycle are revealed, therapy of HDV has not
progressed. To date, treatment options of HDV infection are limited to interferon regimes with
open issues about effectiveness of current approaches. Due to the unsatisfactory results further
studies of novel drugs and therapy protocols are required. In this chapter current treatment
procedures as well as novel therapeutic strategies to combat chronic HDV infection will be
discussed.
2. Epidemiology
It is estimated that 15-20 million of HBsAg positive individuals are infected with HDV, but
these numbers are not accurate because of absence of systematic screening in HBV infected
individuals [12]. Interestingly, HDV infection is worldwide distributed; however the distri‐
bution is not uniform. Areas of HDV high prevalence are: Central Africa, Mediterranean
countries, Middle East and South America, while in Western world HDV infection is limited
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Figure 1. Structure of HDV virion. HDV is composed of outer membrane, HBV envelope proteins within a phospholi‐
pid bilayer, and inner nucleocapsid consisting of viral RNA and hepatitis delta antigens. L-HBsAg=large hepatitis B
surface antigen. M-HBsAg=medium hepatitis B surface antigen. S-HBsAg=small hepatitis B surface antigen. HDV
RNA=hepatitis D virus RNA. L-HDAg=large hepatitis D antigen. S-HDAg=small hepatitis D antigen.
Drug Discovery and Development - From Molecules to Medicine184
to intravenous drug abusers [13]. Decrease of HDV incidence in industrialized world is caused
by improvement of socioeconomic conditions such as implementation of HBV vaccination and
systematic screening of blood and blood products. However, reduction in the number of
infected individuals in developed countries has stopped, mainly due to the increased immi‐
gration from endemic areas [14]. Prevalence of anti-HD among HBsAg positive individuals in
Western Europe has been stable during last decade ranging from 8.5 to 11.0 % [15, 16].
So far, eight HDV genotypes have been described. Most frequent is genotype 1 [17], which is
prevalent worldwide, while genotypes 2 and 4 are mainly found in the Far East and genotype
3 is limited to Amazonian basin [18]. HDV genotypes 5-8 are found in patients originating
from Africa [19]. Different HDV genotypes have impact on variations in clinical course of
disease, thus genotypes 1 and 3 cause more severe disease, while genotype 2 is associated with
milder form. Also, multiple genotypes of HDV can be found in high risk patients [20].
3. Transmission of HDV
HDV, as its helper HBV, is transmitted parenterally through the exposure to the blood and
body fluids. In the developed countries the main route of transmission is by infected syringes
among intravenous drug users. Although, there is an evidence for sexual transmission [21], it
seems that HDV does not have the same rate of sexual transmission as HBV[22]. Due to the
screening of the blood products, there is no more risk of HDV infections for the blood receiving
patients. Despite the fact that HDV is parenterally transmitted, inapparent parenteral trans‐
mission within household [23] represents major route of transmission in the areas of the high
prevalence. Therefore vaccination against HBV of all household members of infected individ‐
ual is the crucial step in prevention of HDV infections. Vertical transmission from mother to
the newborn is rare.
4. Clinical features
As defective virus, HDV replication depends on HbsAg synthesis, therefore HDV can be
transmitted only in the presence of accompanied HBV infection. Based on the previous HBsAg
status of the infected individual two major patterns of infection are distinguished: simultane‐
ous HBV/HDV co-infection or superinfection by HDV of chronic HBsAg carriers [18].
In the simultaneous infection the fate of HDV depends on the host response to the HBV. When
the expression of HBsAg is restrained, the HDV infection may result with abortive response,
while abundance of HBsAg enables the full expression of HDV pathogenicity. As a result of
this interaction between the two viruses, disease expression may vary. Clinically, HDV/HBV
co-infection is usually similar to HBV mono-infection, although acute co-infection can be more
severe and can be manifested as acute liver failure [24]. The rate of progression of HDV
infection to chronic form is equal to that for acute hepatitis B, less than 5% [19].
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Superinfection is defined as HDV infection of a chronically HBV infected individual. Preex‐
isting chronic HBV infection represents perfect environment for replication of defective
hepatitis D virus, resulting with abundant HDV expression and suppression of HBV replica‐
tion. HBV suppression will become permanent, if HDV infection progress to chronic form [20].
Furthermore, superinfection is generally presented as severe acute hepatitis with shorter
incubation time and will exceed to chronic HDV infection in high percentage of patients, up
to 80% [25]. Clinically, HDV superinfection is manifested as a worsening of present HBV
disease or as a new hepatitis in previously undiagnosed HBV infected individual. Along with
detection of HDV serum markers, correct diagnosis of superinfection is clarified by negative
IgM anti-HBc [21].
5. Symptoms and course
Symptoms of acute hepatits D infection are similar to the other forms of viral hepatitis. Initial
phase of acute infection is characterized by nonspecific symptoms such as: fatigue, anorexia,
nausea and lethargy accompanied with high increase of serum alanine aminotransferase and
aspartate aminotransferase. Sometimes this phase is followed with icteric phase, characterized
by jaundice, dark urine, clay-colored stools and elevated levels of serum bilirubin. Acute
hepatitis is more severe in superinfection pattern, due to the fact that preceding HBV infection
facilitates multiplication of HDV. Furthermore, acute disease can occur as fulminant hepatits,
named as acute liver failure (ALF). ALF is a rare form of acute hepatitis; which is more often
seen in acute hepatitis caused by HDV than other hepatothropic viruses. Clinically, ALF starts
with nonspecific symptoms, such as fatigue and malaise followed by jaundice and hepatic
encephalopathy and ultimately leading to coma. ALF is characterized by massive necrosis of
hepatocytes, rapid clinical course; ultimately result with death of individual in 2-10 days.
Without liver transplantation, ALF has lethal outcome in 80% of cases [26].
Choronic hepatitis D is the rarest form among chronic viral hepatitis, although it is the most
severe and most progressive one. Chronic hepatitis D has three times higher risk for cirrhosis
development than HBV chronic infection [27]. Clinically it is initially expressed as acute
hepatitis in the half of the cases, probably due to initial acute superinfection [28]. However,
symptoms of chronic hepatitis D are variable. Chronic hepatitis D can be manifested as fatigue,
malaise and anorexia or its clinical course can be without any symptoms [9]. When cirrhosis
is developed disease may be stable and asymptomatic for a long period or it can be manifested
with complications related to the cirrhotic process. Once developed, a high number of patients
with HDV cirrhosis will die of liver failure or hepatocellular carcinoma unless liver transplan‐
tation is performed [29].
6. Diagnosis
First step in diagnostic procedures is detection of HDV markers in the blood of HBsAg positive
individual, due to the fact that HDV replication is possible only in the presence of HBV.
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Actually, guidelines suggest that all HBsAg positive individuals should be screened for HDV
infection, as well as members of high-risk group’s like intravenous drug users, hemodialysis
patients, health care and public safety workers. Also in the case of clinical deterioration of
chronic HBV infection, superinfection with HDV should be considered.
Specific markers of HDV infection in serum are: Hepatitis D virus RNA, HDAg and anti-HDV.
HDV RNA is detected in serum by molecular hybridization [30] or more sensitive RT-PCR [31],
thus serum HDAg and anti-HDV are detected by enzyme-linked immunosorbent assay
(ELISA) [32] and radioimmunoassay (RIA). During the diagnostic procedure, along with
confirmation of HDV presence, it is necessary to clarify the stage of the infection due to the
differences in clinical course and progonosis. Based on the interactions between two viruses,
three patterns of HDV infections are distinguished: acute HDV/HBV co-infection, acute HDV
infection of HBsAg positive carrier and chronic HDV infection.
Acute HBV/HDV co-infection is characterized with a high titre of IgM anti-HBc, a marker of
acute HBV infection which enables to distinguishing confection from acute HDV superinfec‐
tion. HDAg appears in the early phase of the acute infection and it is only transiently detectable
in serum, unless patient is imunodeficient. Then HDAg can be detected for a longer period
due to the weak immune system [33]. HDV RNA is also detectable in the early phase of acute
infection [34] and represents a sensitive marker for virus replication present in 90% of patients.
Nowdays, an active HDV infection is confirmed by detection of HDV RNA in the serum by
sensitive real time PCR assays [35]. Although, HDV RNA test can be false negative due to the
variability of the genome sequence, so that sero-conversion and detection of IgM anti-HDV is
still helpful to establish diagnosis of acute infection.
In chronic HDV infection the high titre of IgG anti-HD antibodies persist even after viral
clearance. Also, a large proportion of patients has positive IgM antiHD, a characteristic marker
of acute infection. Persistence of anti-HD IgM antibodies indicates progression of disease to
the chronic form. HDV RNA is present in the serum of chronically infected patients as HDAg.
Individual’s positive for HDV serum markers should be subjected to the liver biopsy to
determine histological stage of the liver disease, due to the fact that HDV serum markers or
values of liver test do not reflect severity of liver damage [36]. Also, all the HDV positive
patients should be tested for HCV and HIV because of the high frequency of co-infection with
these parenterally transmitted viruses [37].
7. Treatment
Presence of HBsAg is necessary for the replication of the HDV, hence the therapeutic aim is to
eradicate both pathogens. HDV is considered eradicated if HDV-RNA in serum and HDAg in
the liver are negative 6 months after therapy [24]. Despite the sustained viral response, there
is still a possibility of reactivation of HDV in HBsAg positive individual, due to the limitations
of diagnostic procedures to detect a low level of HDV copies (1000 copies/ml). Experimentally
in animal model, the posibillity to transfer HDV infection with serum diluted up to 10-11 was
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demonstrated [38]. Although HDV is considered eradicated when serum HDV RNA and
HDAg in the liver are persistently undetectable, only eradication of HBsAg represents a
complete cure and it is ultimate goal of HDV treatment. Eradication of virus results in
normalization of ALT levels and stopping of liver fibrosis process, while developed anti HD
antibodies will prevent re-infections [24].
So far only approved therapy for Hepatits D is standard interferon-α (IFN- α). Long-term
administration of high-dose standard IFN- α, 5 million units daily or 9 million units three times
per week for 12 months, results in normalization of alanine aminotransferase serum values,
clearance of serum HDV RNA, and histological improvement in 50 percent of patients with
chronic hepatitis D [39]. High-dose IFN therapy improves the long-term clinical outcome and
survival rate of the patients, even if they have advanced disease and active cirrhosis before
therapy induction [40]. There are still arguments going on with regard to duration of interferon
treatment. Interferon therapy administered through 12 months has better results comparing
to 6 months therapy [39], although prolongation of IFN therapy to 24 months does not result
with increasing response to the treatment [41]. Unfortunately, large number of patients will
appear relapse usually 2-6 months after termination of treatment [39]. Thus interferon therapy
is insufficient for the majority of patients with chronic HDV, characterized with incomplete
sustained viral response and common biochemical and virological relapses after cessation of
treatment [42, 43]. Interferon treatment is often accompanied with numerous side effects,
which requires a continuous supervision of the patients during treatment. Most common side
effects are influenza like symptoms such as fatigue and weight loss [44]. Severe psychiatric
disorders can appear as a result of prolonged high dose interferon therapy [42, 45], which
disables interferon application to the certain number of patients. Another compulsory reason
for cessation of interferon therapy is decompensation of liver disease, due to the fact that high
number of patients has advanced disease and cirrhosis [46, 47].
Lately, pegylated form of interferon-α (Peg-IFN-α) is introduced in therapy of HDV. It is
characterized by longer half-life, which allows longer intervals between drug administrations.
Treatment with Peg-IFN-α showed better response in naive patients and in previous nonres‐
ponders compared to standard IFN-α treatment [48, 49]. Patients not achieving SVR with
standard interferon therapy, may eradicate serum HDV RNA after a 6-month treatment with
Peg-IFN-α [50]. For the lowering of HDV RNA beyond detectable level, it is demonstrated that
even standard doses of Peg-IFN- α are more successful than high doses of standard IFN- α,
although in that case seroconversion of HBsAg is not taken into consideration [51]. However,
the rate of clearance of HBsAg is greater with Peg-IFN-α, but overall clearance and serocon‐
version of HBsAg is low, only in 3-5% of cases [52]. Generally, it is difficult to assess the
effectiveness of IFN-α therapy due to differences in study strategies that examined the effect
of the treatment. Studies usually differ in forms of drugs, doses, duration of the treatment and
patient follow-up period, making comparison of results a difficult task (Table 1.). Considering
these differences in the previous studies, overall sustained viral response varies from 17 to 43
% [53]. Currently the largest hepatitis delta multicenter study is HIDIT I trial, which is carried
out by the German Network of Competence for Viral Hepatitis (Hep-Net) in collaboration with
centers from Turkey and Greece. In total of 90 patients with hepatitis D, the effect of Peg-IFN-
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α-2a in combination with adeofovir versus either drug alone was examined. Overall, 28% of
the patients had sustained viral response after treatment with Peg-IFN-α-2a for 48 weeks, with
no difference in efficacy between combined therapy compared with Peg-IFN-α-2a monother‐
apy [54]. From the results of current studies it is evident that treatment with Peg-IFN-α-2a has
limited efficacy as a therpy of hepatitis delta, thus further investigations of potential tretment
options are needed.
Study and year Patients(n) Therapy
Duration
(weeks) Results
Yurdaydin, 2008.
[74] 39
1st group (n=14), Lamivudine
(100mg/day) plus IFN-α-2a (9
MU/3x week)
vs.
2nd group (n=8), IFN-α-2a
vs.
3rd group (n=17), Lamivudine
48
BR: 1st(64%), 2nd(63%), 3rd(18%)
EOTR: 1st(50%), 2nd(50%),
3rd(12%)
SVR: 1st(36%), 2nd(50%), 3rd(12%)
Combination treatment was not
superior to IFN therapy.
Gheorghe, 2011.
[75] 49 Peg-IFN-α-2b (1.5μg/kg/week) 48
BR: 50%
EOTR: 33.3%
SVR: 25%
Ormeci, 2011.
[76] 18 Peg-IFN-α-2b (1.5μg/kg/week)
96 weeks (n=11)
and 48 weeks
(n=7)
No significant difference between
two groups in terms of HDV-RNA
suppression and ALT
normalisation.
Wedemeyer, 2011.
[77] 90
1st group (n=31) Peg-IFN-α-2a (180
μg/week) plus Adeofovir (10 mg/
daily) vs.
2nd group (n=29) Peg-IFN-α-2a vs.
3rd group(n=30) Adeofovir
48
BR: 1st(32%), 2nd(28%), 3rd(7%)
EOTR: 1st(23%), 2nd(24%), 3rd(0%)
SVR: 1st(26%), 2nd(31%), 3rd(0%)
Karaca, 2012.
[78] 32
Peg-IFN-α-2a (180 μg) or Peg-IFN-
α-2b (1.5 μg/kg) per week 96
EOTR: 50%
SVR: 47%
Kabaçam, 2012.
[79] 13 Entecavir (1 mg/day) 48
Ineffective in chronic hepatitis
delta.
Samiullah, 2012.
[80] 238 Peg-IFN-α-2b (1.5 μg/kg/week) 48
BR: 51.3%
EOTR: 29.8%
SVR: 29.4%
BR: Biochemical response is determined by a normalization of ALT at the end of the treatment.
EOTR: The end of treatment response is defined by a HDV-RNA negative status.
SVR: A sustained virological response is defined by undetectable serum HDV-RNA at six months after the end of treatment.
Table 1. Recent studies for treatment of chronic delta hepatitis
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Last 30 years many antiviral drugs are tested in the therapy of hepatitis D, but with limited
succsess. Particulary it was tested efficiency of nucleoside and nucleotide analogues (NUCs)
such as: lamivudine, adeofovir, famciclovir and entecavir; due to the fact that NUCs have some
therapeutic efficancy against HBV. The effect of tenofovir was observed in a group of patients
with concomitant presence of HCV, HBV and HDV infection. It seems that the prior long term
treatment with lamivudine and tenofovir before introduction of IFN therapy might help
fastering decline of HDV RNA copies in such patients. However, seroconversion of HBsAg
was not observed. Patients who suffer from multiple infections with HCV, HBV and HDV
present another group difficult to treat. Unfortunately, the consequence is a progressive liver
fibrosis. It is shown that neither IFN monotherapy or combination therapy with NUCs and
IFN are effective. Those patients are less sensitive to IFN therapy [55]. Babiker et al. report the
case of successful depletion of serum HDV RNA in a patient with acute HDV superinfection
due to 65 weeks treatment with tenofovir and lamivudine. But, after the cessation of the
treatment HDV RNA levels began to increase [56]. Another combination therapy is the therapy
with entecavir and PEG IFNα-2a. In this case also, quantitative HBsAg was used as the
treatment response guidance for dual infection with HBV and HDV. The seroconversion of
HBsAg and undetectable HDV RNA levels were achieved after 35 months of such therapy. In
this patient, the stage of liver fibrosis has also improved significantly. The consolidation
therapy during next 12 months after the seroconversion was continued and the patient
remained seronegative during 12 months after cessation of the therapy [57].
Possible new drug candidates for the therapy are the ones affecting the interaction between
HD virion and HBsAg, as well as posttranslational modifications of HDV proteins, such as
prenylation. Also, it seems IFN- λ could be possible alternative for IFN-α because in the
treatment of chronic hepatitis C, IFN- λ proved to cause less side effects [53].
8. Liver transplantation in HDV patients
HDV infection is characterized with more severe disease than HBV monoinfection. Studies
showed two times higher relative risk of cirrhosis and threefold risk increase of hepatocellular
carcinoma in patients coinfected with HBV and HDV compared with HBV monoinfection [27,
58]. Consequently, liver transplantation (LT) represents only therapeutic option for the
patients with end-stage liver disease, as well as for hepatocellular carcinoma and fulminant
hepatitis due to the coinfection or superinfection with HDV and HBV.
Prevention of allograft reinfection is the main requirement for the long term survival. Major
risk factor predicitng HBV-HDV recurrence after LT is a high level of HBV DNA (>105 copies/
ml) at transplant, fortunately that is unusal feature of HDV disease course [59]. Therefore,
patients coinfected with HBV and HDV generally do not require pretransplant antiviral B
therapy. In case when pretransplant antiviral treatment is needed, entecavir or teneofovir are
preferred rather than lamivudine, while IFN therapy is not recommended during the pre‐
transplant period. Other predictors of a low risk of HBV-HDV recurrence are low levels of
HBV replication markers, HDV coinfection and fulminant hepatitis [60]. Coinfection with
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human immunodeficiency virus and recurrence of HCC represent a risk factors for HBV
recurrence [61, 62].
The patient's prognosis and overall outcome after LT is on satisfactory level with current
posttransplant therapy. Golden standard for prevention of recurrent disease is combination
of hyperimmune serum against HBV(HBIg) and potent nucleoside analogue. Therapeutic
strategy of low dose intramuscular HBIg in combination with lamivudine is the most cost-
effective profilaxis [63], with the rates of the recurrence level as low as 4% at 4 years [64].
Therefore, the outcome of LT due to HDV related liver disease is similar to or better than in
other indications of LT [65, 66].
Due to LT, HDV RNA becomes negative within the first days after transplantation, followed
by a decline of HbsAg with almost identical pattern. However, HDVAg can be detected in the
hepatocytes of the graft for several months after treatment [54]. This HDV latency in the graft
represents a potential source of HDV recurrence, because of possible HBV superinfection and
reexpression of HBsAg. Thus, transplanted patients should be monitored for HbsAG and HBV
DNA every 3 months and for HDV RNA every 6 months.
9. Perspectives for a vaccine development against HDV
Since the details in pathophysiologic respose to HDV infection still aren't enlightened, there
are difficulties in finding the effective vaccine against it. In the case of HDV infection, the
antigen is nucleoprotein and the imunization means the activation of T cells (CD4+ and CD8+)
which would destroy infected cells and prevent replication of the virus. Preclinical studies
have been done on woodchuks. In this model of chronically infected woodchuks with
woodchuck hepatitis virus (WHV), it is possible to achieve the superinfection with HDV. So
far, T cell vaccine prevented the coinfection with WHV- HDV, but it failed to prevent the
superinfection of chronic carriers of WHV. Further studies have to be done to resolve the
problem of preventing the superinfection by stimulating T cells. This would mean that chronic
carriers would have to be vaccinated frequently to activate a large number of T cells before the
patient is exposed to HDV. [67]
10. Novel therapeutic strategies for future treatment
So far, the treatment outcome of hepatitis delta is not satisfactory. Thus, new therapy aproaches
are necessary (Figure 2.). Interferon-α targets the HbsAg, whose depletion is crucial for
succesful treatment of hepatitis delta. The major difficulty with such therapy are numerous
adverse effects, since IFN-α receptors are also present in other tissues than hepatic. Additional
problem is the necessity of long term application of IFN-α to achieve therapeutic response.
Better candidate could be IFN- λ, since its receptors are present only on epithelial cells [68]. It
has been shown that pegylated IFN- λ used as monotherapy, or in combination with ribavirin,
has significant antiviral activity against hepatitis C virus. Also, as expected, it causes less
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undesirable side effects. [69] Further studies must be done to evaluate the effectivness of IFN-
λ in treatment od chronic hepatitis delta.
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HDV RNP= hepatitis D virus ribonucleoprotein. HBsAg= hepatitis B surface antigen.
HSPG=highly sulphated proteoglycans. HDAg=hepatitis D antigen.
Figure 2. Potential drug targets in HDV treatment. 1. Neutralizing of negativly charged HSPG may prevent HDV and
HBV attachment to hepatocyte membrane. 2. Gene therapy targets genes which encode HDAg 3. Inhibition of HDV
ribozymes would prevent virus replication, 4. Interferring with posttranslational modifications of HDVAg enables viri‐
on assembly.
Other strategy for therapy development is to interfere with posttranslational modifications of
HDVAg. Such modifications are prenylation, acetylation, metylation and phosphorylation of
HDVAg. Prenylation inhibitors proved effective in cell culture model and are currently in
clinical studies. [54] Drugs interferring with other types of HDV posttranslational modifica‐
tions haven't been developed yet. [70]
Since HDV genome is too small to code all the necessary particles for it's own replication, it
almost entirely depends on the host's replication mechanisms. For example, it deceives host's
RNA polymerases so they copy HDV genome. HDV replication is known as rolling replication
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mechanism, meaning that HDV circular genome is elongated into multimeric linear transcripts
and than cleaved into multiple genome size monomers by it's own RNA. This type of RNA is
known as ribozyme, which is actually HDV RNA with enzymatic activity.
Small interfering RNAs (siRNAs) are up to 25 nucleotides long double stranded RNAs which
silence particular gene by binding to mRNA. After binding to target mRNA,siRNA causes it's
degradation. In therapy of HDV infection, silencing gene which codes LHD-Ag would disable
HD virion replication [16].
Ribozymes can also serve as target for therapy. It has been shown that amoxicillin, apramycin
and ristomycin in complex with copper (II) bind to HDV ribozymes and inhibit them. [71]
Further studies are necessary to investigate the therapeutic potential of such treatment.
Not only large HDAg (LHDAg) is important for the lifecycle of hepatitis delta virus, but also
the small delta antigen protein (SHDAg). Therefore, it can also be the target for new drugs in
development for HDV treatment.
It has been shown that the negatively charged highly sulphated proteoglycanes (HSPG) play
a role in both HBV and HDV attachement to hepatocyte membrane. Those weak forces between
opposite charged subjects enable virus attachment to the cell. [72] This kind of target could be
good for developing the drug which would prevent binding of both HBV and HDV to
hepatocyte surface by neutralizing the negative charge of HSPG.
Gene therapy would target HDVAg, which is proved to have crucial role in lifecycle of HDV.
Design of specific molecule which binds to gene which encodes delta antigen is in progess.
Some computational analyses have been done to simulate the silencing of target gene. [73]
11. Conclusions
HDV is an unusal, defective hepatotropic virus which causes severe acute hepatitis and most
progressive chronic viral hepatitis. Despite the efforts in eradication of HDV, as its obligatory
helper HBV, prevalence of HDV in developed countries remains stable and represents a
relevant public health concern. Current conventional therapy of hepatitis delta is characterized
with poor overall response, thus further investigations of novel treatment options are needed.
Continuous research of virology and pathogenesis is necessary to provide fundamentals for
development of novel approaches in treatment of HDV.
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